GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs
Polymorphisms in the human dopamine transporter (DAT) are associated with bipolar endophenotype. Based on this, the acute inhibition of DAT using GBR12909 causes behavioral alterations that are prevented by valproate (VAL), being related to a mania-like model. Herein our first aim was to analyze beh...
Gespeichert in:
Veröffentlicht in: | Metabolic brain disease 2015-10, Vol.30 (5), p.1207-1215 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1215 |
---|---|
container_issue | 5 |
container_start_page | 1207 |
container_title | Metabolic brain disease |
container_volume | 30 |
creator | Queiroz, Ana Isabelle G. de Araújo, Maíra Moraes da Silva Araújo, Tatiane de Souza, Greicy Coelho Cavalcante, Lígia Menezes de Jesus Souza Machado, Michel de Lucena, David Freitas Quevedo, João Macêdo, Danielle |
description | Polymorphisms in the human dopamine transporter (DAT) are associated with bipolar endophenotype. Based on this, the acute inhibition of DAT using GBR12909 causes behavioral alterations that are prevented by valproate (VAL), being related to a mania-like model. Herein our first aim was to analyze behavioral and brain oxidative alterations during a 24 h period post-GBR12909 to better characterize this model. Our second aim was to determine the preventive effects of lithium (Li) or VAL 2 h post-GBR12909. For this, adult male mice received GBR12909 or saline being evaluated at 2, 4, 8, 12 or 24 h post-administration. Hyperlocomotion, levels of reduced glutathione (GSH) and lipid peroxidation in brain areas were assessed at all these time-points. GBR12909 caused hyperlocomotion at 2 and 24 h. Rearing behavior increased only at 2 h. GSH levels decreased in the hippocampus and striatum at the time points of 2, 4, 8 and 12 h. Increased lipid peroxidation was detected at the time-points of 2 and 12 h in all brain areas studied. At the time-point of 2 h post-GBR12909 Li prevented the hyperlocomotion and rearing alterations, while VAL prevented only rearing alterations. Both drugs prevented pro-oxidative changes. In conclusion, we observed that the main behavioral and oxidative alterations took place at the time-period of 2 h post-GBR12909, what points to this time-period as the best for the assessment of alterations in this model. Furthermore, the present study expands the predictive validity of the model by the determination of the preventive effects of Li. |
doi_str_mv | 10.1007/s11011-015-9697-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722184638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1709716041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-f99c32176052a450a9fa7f1bce25cf9cfd5c3e14602dcd3a9a16ab82cca210953</originalsourceid><addsrcrecordid>eNqNkU-L1TAUxYMoznP0A7iRgBsXVnOTJnlxp4OOwoAgui63-fPM0DbPpB3Ub-K3NZ2OIoLgJlmc3zmXew8hD4E9A8b08wLAABoGsjHK6EbdIjuQWjRaKHmb7Nh-LxvdGnZC7pVyyRgTEsxdcsIV04ILviM_zl99oMANMxTdGKdY5oxzTBPFQrG-UxxxoGNyfqAp0D4e04CZjlXAF3SOo6c2Lbn4a9V_xquYMg5PaZ8xTjR9ja7mXXmKw-y36DXYUR-Ct_PqGlNytMzYxyF-j9OBurwcyn1yJ-BQ_IOb_5R8evP649nb5uL9-buzlxeNlS3MTTDGCg5aMcmxlQxNQB2gt55LG4wNTlrhoVWMO-sEGgSF_Z5bixyYkeKUPNlyjzl9WXyZuzEW64cBJ5-W0oHmHPatEvv_QJnRoFgLFX38F3pZrzTVRa4pCQr4Ohs2yuZUSvahO-Z67_ytA9atFXdbxV2tuFsr7lT1PLpJXvrRu9-OX51WgG9AqdJ08PmP0f9M_Qlq3bGB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709516125</pqid></control><display><type>article</type><title>GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Queiroz, Ana Isabelle G. ; de Araújo, Maíra Moraes ; da Silva Araújo, Tatiane ; de Souza, Greicy Coelho ; Cavalcante, Lígia Menezes ; de Jesus Souza Machado, Michel ; de Lucena, David Freitas ; Quevedo, João ; Macêdo, Danielle</creator><creatorcontrib>Queiroz, Ana Isabelle G. ; de Araújo, Maíra Moraes ; da Silva Araújo, Tatiane ; de Souza, Greicy Coelho ; Cavalcante, Lígia Menezes ; de Jesus Souza Machado, Michel ; de Lucena, David Freitas ; Quevedo, João ; Macêdo, Danielle</creatorcontrib><description>Polymorphisms in the human dopamine transporter (DAT) are associated with bipolar endophenotype. Based on this, the acute inhibition of DAT using GBR12909 causes behavioral alterations that are prevented by valproate (VAL), being related to a mania-like model. Herein our first aim was to analyze behavioral and brain oxidative alterations during a 24 h period post-GBR12909 to better characterize this model. Our second aim was to determine the preventive effects of lithium (Li) or VAL 2 h post-GBR12909. For this, adult male mice received GBR12909 or saline being evaluated at 2, 4, 8, 12 or 24 h post-administration. Hyperlocomotion, levels of reduced glutathione (GSH) and lipid peroxidation in brain areas were assessed at all these time-points. GBR12909 caused hyperlocomotion at 2 and 24 h. Rearing behavior increased only at 2 h. GSH levels decreased in the hippocampus and striatum at the time points of 2, 4, 8 and 12 h. Increased lipid peroxidation was detected at the time-points of 2 and 12 h in all brain areas studied. At the time-point of 2 h post-GBR12909 Li prevented the hyperlocomotion and rearing alterations, while VAL prevented only rearing alterations. Both drugs prevented pro-oxidative changes. In conclusion, we observed that the main behavioral and oxidative alterations took place at the time-period of 2 h post-GBR12909, what points to this time-period as the best for the assessment of alterations in this model. Furthermore, the present study expands the predictive validity of the model by the determination of the preventive effects of Li.</description><identifier>ISSN: 0885-7490</identifier><identifier>EISSN: 1573-7365</identifier><identifier>DOI: 10.1007/s11011-015-9697-6</identifier><identifier>PMID: 26073232</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Affect - drug effects ; Affect - physiology ; Animals ; Antimanic Agents - pharmacology ; Antimanic Agents - therapeutic use ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Bipolar Disorder - drug therapy ; Bipolar Disorder - metabolism ; Brain - drug effects ; Brain - metabolism ; Disease Models, Animal ; Dopamine Uptake Inhibitors - pharmacology ; Dopamine Uptake Inhibitors - therapeutic use ; Lipid Peroxidation - drug effects ; Lipid Peroxidation - physiology ; Male ; Metabolic Diseases ; Mice ; Neurology ; Neurosciences ; Oncology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Piperazines - pharmacology ; Piperazines - therapeutic use ; Research Article ; Time Factors</subject><ispartof>Metabolic brain disease, 2015-10, Vol.30 (5), p.1207-1215</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-f99c32176052a450a9fa7f1bce25cf9cfd5c3e14602dcd3a9a16ab82cca210953</citedby><cites>FETCH-LOGICAL-c541t-f99c32176052a450a9fa7f1bce25cf9cfd5c3e14602dcd3a9a16ab82cca210953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11011-015-9697-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11011-015-9697-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26073232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Queiroz, Ana Isabelle G.</creatorcontrib><creatorcontrib>de Araújo, Maíra Moraes</creatorcontrib><creatorcontrib>da Silva Araújo, Tatiane</creatorcontrib><creatorcontrib>de Souza, Greicy Coelho</creatorcontrib><creatorcontrib>Cavalcante, Lígia Menezes</creatorcontrib><creatorcontrib>de Jesus Souza Machado, Michel</creatorcontrib><creatorcontrib>de Lucena, David Freitas</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><creatorcontrib>Macêdo, Danielle</creatorcontrib><title>GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs</title><title>Metabolic brain disease</title><addtitle>Metab Brain Dis</addtitle><addtitle>Metab Brain Dis</addtitle><description>Polymorphisms in the human dopamine transporter (DAT) are associated with bipolar endophenotype. Based on this, the acute inhibition of DAT using GBR12909 causes behavioral alterations that are prevented by valproate (VAL), being related to a mania-like model. Herein our first aim was to analyze behavioral and brain oxidative alterations during a 24 h period post-GBR12909 to better characterize this model. Our second aim was to determine the preventive effects of lithium (Li) or VAL 2 h post-GBR12909. For this, adult male mice received GBR12909 or saline being evaluated at 2, 4, 8, 12 or 24 h post-administration. Hyperlocomotion, levels of reduced glutathione (GSH) and lipid peroxidation in brain areas were assessed at all these time-points. GBR12909 caused hyperlocomotion at 2 and 24 h. Rearing behavior increased only at 2 h. GSH levels decreased in the hippocampus and striatum at the time points of 2, 4, 8 and 12 h. Increased lipid peroxidation was detected at the time-points of 2 and 12 h in all brain areas studied. At the time-point of 2 h post-GBR12909 Li prevented the hyperlocomotion and rearing alterations, while VAL prevented only rearing alterations. Both drugs prevented pro-oxidative changes. In conclusion, we observed that the main behavioral and oxidative alterations took place at the time-period of 2 h post-GBR12909, what points to this time-period as the best for the assessment of alterations in this model. Furthermore, the present study expands the predictive validity of the model by the determination of the preventive effects of Li.</description><subject>Affect - drug effects</subject><subject>Affect - physiology</subject><subject>Animals</subject><subject>Antimanic Agents - pharmacology</subject><subject>Antimanic Agents - therapeutic use</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Bipolar Disorder - metabolism</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Disease Models, Animal</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Dopamine Uptake Inhibitors - therapeutic use</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Lipid Peroxidation - physiology</subject><subject>Male</subject><subject>Metabolic Diseases</subject><subject>Mice</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Oncology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Piperazines - pharmacology</subject><subject>Piperazines - therapeutic use</subject><subject>Research Article</subject><subject>Time Factors</subject><issn>0885-7490</issn><issn>1573-7365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU-L1TAUxYMoznP0A7iRgBsXVnOTJnlxp4OOwoAgui63-fPM0DbPpB3Ub-K3NZ2OIoLgJlmc3zmXew8hD4E9A8b08wLAABoGsjHK6EbdIjuQWjRaKHmb7Nh-LxvdGnZC7pVyyRgTEsxdcsIV04ILviM_zl99oMANMxTdGKdY5oxzTBPFQrG-UxxxoGNyfqAp0D4e04CZjlXAF3SOo6c2Lbn4a9V_xquYMg5PaZ8xTjR9ja7mXXmKw-y36DXYUR-Ct_PqGlNytMzYxyF-j9OBurwcyn1yJ-BQ_IOb_5R8evP649nb5uL9-buzlxeNlS3MTTDGCg5aMcmxlQxNQB2gt55LG4wNTlrhoVWMO-sEGgSF_Z5bixyYkeKUPNlyjzl9WXyZuzEW64cBJ5-W0oHmHPatEvv_QJnRoFgLFX38F3pZrzTVRa4pCQr4Ohs2yuZUSvahO-Z67_ytA9atFXdbxV2tuFsr7lT1PLpJXvrRu9-OX51WgG9AqdJ08PmP0f9M_Qlq3bGB</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Queiroz, Ana Isabelle G.</creator><creator>de Araújo, Maíra Moraes</creator><creator>da Silva Araújo, Tatiane</creator><creator>de Souza, Greicy Coelho</creator><creator>Cavalcante, Lígia Menezes</creator><creator>de Jesus Souza Machado, Michel</creator><creator>de Lucena, David Freitas</creator><creator>Quevedo, João</creator><creator>Macêdo, Danielle</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs</title><author>Queiroz, Ana Isabelle G. ; de Araújo, Maíra Moraes ; da Silva Araújo, Tatiane ; de Souza, Greicy Coelho ; Cavalcante, Lígia Menezes ; de Jesus Souza Machado, Michel ; de Lucena, David Freitas ; Quevedo, João ; Macêdo, Danielle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-f99c32176052a450a9fa7f1bce25cf9cfd5c3e14602dcd3a9a16ab82cca210953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Affect - drug effects</topic><topic>Affect - physiology</topic><topic>Animals</topic><topic>Antimanic Agents - pharmacology</topic><topic>Antimanic Agents - therapeutic use</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Bipolar Disorder - metabolism</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Disease Models, Animal</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Dopamine Uptake Inhibitors - therapeutic use</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Lipid Peroxidation - physiology</topic><topic>Male</topic><topic>Metabolic Diseases</topic><topic>Mice</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Oncology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Piperazines - pharmacology</topic><topic>Piperazines - therapeutic use</topic><topic>Research Article</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Queiroz, Ana Isabelle G.</creatorcontrib><creatorcontrib>de Araújo, Maíra Moraes</creatorcontrib><creatorcontrib>da Silva Araújo, Tatiane</creatorcontrib><creatorcontrib>de Souza, Greicy Coelho</creatorcontrib><creatorcontrib>Cavalcante, Lígia Menezes</creatorcontrib><creatorcontrib>de Jesus Souza Machado, Michel</creatorcontrib><creatorcontrib>de Lucena, David Freitas</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><creatorcontrib>Macêdo, Danielle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolic brain disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Queiroz, Ana Isabelle G.</au><au>de Araújo, Maíra Moraes</au><au>da Silva Araújo, Tatiane</au><au>de Souza, Greicy Coelho</au><au>Cavalcante, Lígia Menezes</au><au>de Jesus Souza Machado, Michel</au><au>de Lucena, David Freitas</au><au>Quevedo, João</au><au>Macêdo, Danielle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs</atitle><jtitle>Metabolic brain disease</jtitle><stitle>Metab Brain Dis</stitle><addtitle>Metab Brain Dis</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>30</volume><issue>5</issue><spage>1207</spage><epage>1215</epage><pages>1207-1215</pages><issn>0885-7490</issn><eissn>1573-7365</eissn><abstract>Polymorphisms in the human dopamine transporter (DAT) are associated with bipolar endophenotype. Based on this, the acute inhibition of DAT using GBR12909 causes behavioral alterations that are prevented by valproate (VAL), being related to a mania-like model. Herein our first aim was to analyze behavioral and brain oxidative alterations during a 24 h period post-GBR12909 to better characterize this model. Our second aim was to determine the preventive effects of lithium (Li) or VAL 2 h post-GBR12909. For this, adult male mice received GBR12909 or saline being evaluated at 2, 4, 8, 12 or 24 h post-administration. Hyperlocomotion, levels of reduced glutathione (GSH) and lipid peroxidation in brain areas were assessed at all these time-points. GBR12909 caused hyperlocomotion at 2 and 24 h. Rearing behavior increased only at 2 h. GSH levels decreased in the hippocampus and striatum at the time points of 2, 4, 8 and 12 h. Increased lipid peroxidation was detected at the time-points of 2 and 12 h in all brain areas studied. At the time-point of 2 h post-GBR12909 Li prevented the hyperlocomotion and rearing alterations, while VAL prevented only rearing alterations. Both drugs prevented pro-oxidative changes. In conclusion, we observed that the main behavioral and oxidative alterations took place at the time-period of 2 h post-GBR12909, what points to this time-period as the best for the assessment of alterations in this model. Furthermore, the present study expands the predictive validity of the model by the determination of the preventive effects of Li.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>26073232</pmid><doi>10.1007/s11011-015-9697-6</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0885-7490 |
ispartof | Metabolic brain disease, 2015-10, Vol.30 (5), p.1207-1215 |
issn | 0885-7490 1573-7365 |
language | eng |
recordid | cdi_proquest_miscellaneous_1722184638 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Affect - drug effects Affect - physiology Animals Antimanic Agents - pharmacology Antimanic Agents - therapeutic use Biochemistry Biomedical and Life Sciences Biomedicine Bipolar Disorder - drug therapy Bipolar Disorder - metabolism Brain - drug effects Brain - metabolism Disease Models, Animal Dopamine Uptake Inhibitors - pharmacology Dopamine Uptake Inhibitors - therapeutic use Lipid Peroxidation - drug effects Lipid Peroxidation - physiology Male Metabolic Diseases Mice Neurology Neurosciences Oncology Oxidative Stress - drug effects Oxidative Stress - physiology Piperazines - pharmacology Piperazines - therapeutic use Research Article Time Factors |
title | GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T22%3A51%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GBR%2012909%20administration%20as%20an%20animal%20model%20of%20bipolar%20mania:%20time%20course%20of%20behavioral,%20brain%20oxidative%20alterations%20and%20effect%20of%20mood%20stabilizing%20drugs&rft.jtitle=Metabolic%20brain%20disease&rft.au=Queiroz,%20Ana%20Isabelle%20G.&rft.date=2015-10-01&rft.volume=30&rft.issue=5&rft.spage=1207&rft.epage=1215&rft.pages=1207-1215&rft.issn=0885-7490&rft.eissn=1573-7365&rft_id=info:doi/10.1007/s11011-015-9697-6&rft_dat=%3Cproquest_cross%3E1709716041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1709516125&rft_id=info:pmid/26073232&rfr_iscdi=true |